288 related articles for article (PubMed ID: 25370534)
1. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Shen L; Sundstedt A; Ciesielski M; Miles KM; Celander M; Adelaiye R; Orillion A; Ciamporcero E; Ramakrishnan S; Ellis L; Fenstermaker R; Abrams SI; Eriksson H; Leanderson T; Olsson A; Pili R
Cancer Immunol Res; 2015 Feb; 3(2):136-48. PubMed ID: 25370534
[TBL] [Abstract][Full Text] [Related]
2. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
Olsson A; Nakhlé J; Sundstedt A; Plas P; Bauchet AL; Pierron V; Bruetschy L; Deronic A; Törngren M; Liberg D; Schmidlin F; Leanderson T
J Immunother Cancer; 2015; 3():53. PubMed ID: 26673090
[TBL] [Abstract][Full Text] [Related]
3. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
4. Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Fan R; Satilmis H; Vandewalle N; Verheye E; Vlummens P; Maes A; Muylaert C; De Bruyne E; Menu E; Evans H; Chantry A; De Beule N; Hose D; Törngren M; Eriksson H; Vanderkerken K; Maes K; Breckpot K; De Veirman K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650020
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
Deronic A; Tahvili S; Leanderson T; Ivars F
BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.
Hossain F; Al-Khami AA; Wyczechowska D; Hernandez C; Zheng L; Reiss K; Valle LD; Trillo-Tinoco J; Maj T; Zou W; Rodriguez PC; Ochoa AC
Cancer Immunol Res; 2015 Nov; 3(11):1236-47. PubMed ID: 26025381
[TBL] [Abstract][Full Text] [Related]
7. Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity.
Kaimala S; Mohamed YA; Nader N; Issac J; Elkord E; Chouaib S; Fernandez-Cabezudo MJ; Al-Ramadi BK
Cancer Immunol Immunother; 2014 Jun; 63(6):587-99. PubMed ID: 24668365
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action of tasquinimod on the tumour microenvironment.
Raymond E; Dalgleish A; Damber JE; Smith M; Pili R
Cancer Chemother Pharmacol; 2014 Jan; 73(1):1-8. PubMed ID: 24162378
[TBL] [Abstract][Full Text] [Related]
9. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model.
Meyer C; Sevko A; Ramacher M; Bazhin AV; Falk CS; Osen W; Borrello I; Kato M; Schadendorf D; Baniyash M; Umansky V
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17111-6. PubMed ID: 21969559
[TBL] [Abstract][Full Text] [Related]
10. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.
Dalrymple SL; Becker RE; Zhou H; DeWeese TL; Isaacs JT
Prostate; 2012 May; 72(6):638-48. PubMed ID: 21837778
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
12. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release.
Jayaraman P; Parikh F; Lopez-Rivera E; Hailemichael Y; Clark A; Ma G; Cannan D; Ramacher M; Kato M; Overwijk WW; Chen SH; Umansky VY; Sikora AG
J Immunol; 2012 Jun; 188(11):5365-76. PubMed ID: 22529296
[TBL] [Abstract][Full Text] [Related]
13. Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment.
Wallecha A; Singh R; Malinina I
J Immunother; 2013; 36(9):468-76. PubMed ID: 24145358
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
15. Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects.
Mehta AR; Armstrong AJ
Ther Adv Urol; 2016 Feb; 8(1):9-18. PubMed ID: 26834836
[TBL] [Abstract][Full Text] [Related]
16. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
17. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
[TBL] [Abstract][Full Text] [Related]
18. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
[TBL] [Abstract][Full Text] [Related]
19. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Chen M; Xiang R; Wen Y; Xu G; Wang C; Luo S; Yin T; Wei X; Shao B; Liu N; Guo F; Li M; Zhang S; Li M; Ren K; Wang Y; Wei Y
Sci Rep; 2015 Sep; 5():14421. PubMed ID: 26394925
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210.
Noman MZ; Janji B; Hu S; Wu JC; Martelli F; Bronte V; Chouaib S
Cancer Res; 2015 Sep; 75(18):3771-87. PubMed ID: 26206559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]